“In the case of bacterial meningitis the prognosis worsens by 30% every hour”

by Laura Richards – Editor-in-Chief

Viruses, fungi, bacteria and even ⁤parasites ‌can attack the ⁣human brain and cause dangerous damage. Now a new procedure will make diagnosis ⁣easier and particularly useful in​ mysterious cases, which are also on the rise in Germany.

A newly ⁣developed genetic ⁣test can check brain fluid for ⁣almost all known pathogens:‍ viruses, bacteria, fungi and parasites. In this‍ way, the cause of brain ⁣infections can​ be determined relatively ⁤reliably and appropriate ​therapy can be initiated, writes an American research team after a seven-year study with samples.

According to‍ the team published in the journal Nature Medicine, central nervous system (CNS) infections​ such as meningitis, encephalitis and ⁣myelitis can be life-threatening.​ explained. Rapid diagnosis and treatment are often‌ essential to avoid serious consequences. Currently, several test procedures are often combined to clarify, but in half of the cases,⁤ for example, the cause‌ of meningoencephalitis cannot be ‌clarified.

“This topic is extremely important,” confirmed neurologist Helge ⁢Roland Topka, head physician at the Bogenhausen clinic in Munich, who was not involved⁤ in the study. The spokesperson ‌of the Commission for Neurological Emergency Medicine of the German Neurological‌ Society (DGN) spoke⁣ of ‍a “fascinating‍ technology”: “This system is able‍ to ‍find pathogens ​that you wouldn’t expect.”

The fully automated process that Chiu helped develop, called next-generation metagenomic⁣ sequencing (mNGS), analyzes brain ‍fluid samples for different⁣ types of pathogens. The ‌genetic material⁣ circulating in the brain fluid is isolated and sequenced. These sequences are then compared⁢ with⁣ databases and assigned to different ⁢organisms.

In the current one Study the team presents the results‌ of tests of⁢ samples sent to the laboratory and examined⁤ there from 2016 ‍to 2023. The evaluation detected an infection in one in seven (697 samples; ⁤14.4%) of the 4828 total samples. The team⁣ detected DNA​ viruses in

The team also tested various diagnostic procedures on approximately‌ 1,160 samples from ‍San Francisco University Hospital: in 22% of the samples, only the new procedure identified the ‍responsible pathogen.

With a rate‌ of 99.6% for the so-called specificity, false positives were‍ extremely rare. The so-called sensitivity, however, ⁣was weaker, around 63%. In just under two-thirds of patients ‌with brain infection, a pathogen was actually identified. But this is still significantly better than antibody tests, whose sensitivity reaches only 29%, ⁤and direct testing methods for some ‌pathogens, ‍which would reach 46%.

However, the group writes: “With ⁢an overall sensitivity of​ 63.1%, the mNGS method is⁣ not sufficient to replace conventional microbiological tests.” to ‍a pathogen for ‍a short time such‍ as West ‌Nile virus. Or infections in which the triggers ‍colonize only ‌parts of the brain ⁤tissue ‍and do not appear‍ in ⁣the cerebrospinal fluid.

According to​ Munich-based DGN expert Topka, the biggest ⁤weakness of‌ the procedure for use in emergency neurology is the ⁣analysis time, which⁢ currently takes a good 3.5‍ days. “We often‍ only have an extremely ⁣short period ‌of time to ⁣start​ therapy. In case of bacterial‌ meningitis the prognosis worsens ⁢by 30% every hour.” You ⁣have to react immediately,‌ often in⁢ cases of ​suspicion.

Pathogens ⁤that you wouldn’t suspect

For clarification and subsequent optimized therapy, a rapid multiplex PCR test⁢ is currently used, which ‍analyzes the brain fluid in just over an hour, but only for around a dozen of the most common pathogens.

In contrast, the method‌ presented by Chiu is capable of “finding pathogens that you are not specifically looking for.” This is extremely important, especially in mysterious cases without strong time pressure.

Chiu’s‍ group also highlights ⁤the benefits of this‍ approach. This ‍applies especially⁢ to those ‌pathogens that cannot ‌be cultured in ‌the laboratory, such as the Lyme disease bacterium Borrelia burgdorferi​ and Bartonella ⁤henselae, the cause ⁣of cat scratch‍ disease, ⁢to diagnose viral infections and to ⁣clarify rare⁢ but extremely dangerous causes , such as amoebic encephalitis or amoebosis of⁤ swimming ⁣pools,‌ as well​ as in investigations in case of epidemics.

After an outbreak of fungal meningitis in Mexico in 2023, the ​method identified the pathogen Fusarium solani in the first US ‌patient and⁢ thus alerted US health authorities to the problem.

Infections with rare pathogens are also increasing in Germany, Topka said, mainly due to long-distance travel and ‍global trade. The ​new approach is certainly​ useful for clarifying mysterious ⁤brain‌ infections. “If the process ⁤were a little⁤ faster, this would be ‍the solution to many ‍infection problems,” ⁤Topka ⁢says.

The research group⁤ estimates that the cost of the ​test is around 3,000 dollars (just under 2,800 euros). This means that initially the procedure is only suitable for rich countries. However, costs⁣ may decrease ⁤in the future.

In ⁢the specialized magazine “Nature Communications” provides Chiu ​and another team are ⁣introducing a similar ‍mNGS procedure: this can determine ‍the viral causes of respiratory infections within⁣ a ‌day. ⁢In this case the ⁢reliability of the results compared to the PCR standard is almost 94%.

dpa/sk

case #bacterial #meningitis #prognosis‍ #worsens #hour

What is the‌ role ​of next-generation sequencing in ​diagnosing CNS infections?

Interview Script: Time.news Editor and Neurology Expert

[Setting: A virtual meeting room. The Time.news editor, Alex, sits comfortably with a notepad, while Dr. Helge Roland Topka, a renowned neurologist from the Bogenhausen clinic in Munich, joins the call.]

Alex: Good afternoon, Dr. Topka! Thank you for⁢ joining me‌ today to discuss ​this groundbreaking genetic test for diagnosing ​brain infections.

Dr. Topka: Good afternoon, Alex! It’s a pleasure to be here and discuss such an important advancement in neurology.

Alex: Absolutely! The study published in Nature Medicine highlights how this new ⁤next-generation​ metagenomic sequencing, or mNGS, can identify a wide array of pathogens ‍in brain fluid. Can you explain‍ the significance⁤ of this development to our viewers?

Dr. Topka: Certainly! ‌CNS infections, like⁣ meningitis‌ and encephalitis, can have serious, life-threatening consequences. Rapid and‍ accurate​ diagnosis⁤ is crucial in these cases. Traditional methods often ⁣involve multiple tests⁣ and can leave many cases unresolved. The new mNGS technique allows for simultaneous testing for viruses, bacteria, fungi, and even parasites, ‍which enhances ⁢our ability to pinpoint the cause of brain infections more reliably.

Alex: That sounds promising! The study found detectable infections in 14.4% of the samples examined. What does that statistic tell us about the prevalence of these infections?

Dr. Topka: ‍It indicates that ⁢CNS infections may be more common than previously recognized, but also highlights⁢ the challenges we face in diagnosing them. While the mNGS⁢ method shows significant potential, it‍ still doesn’t identify pathogens in⁣ all cases—63% sensitivity means one in three infections may still go undetected.

Alex: That’s a‍ critical point. The ⁣quick ⁤analysis is crucial, yet the‌ current process takes about 3.5 days. How does that time frame impact clinical⁤ decisions?

Dr. Topka: In emergency neurology, every ⁣minute counts, especially ⁣for conditions like⁤ bacterial meningitis, where outcomes worsen significantly ‍over time. Current rapid⁢ tests can provide results within⁤ an ⁤hour but are limited⁢ to ​common pathogens. mNGS can uncover unexpected pathogens, which is extremely useful in puzzling cases—though it can’t replace rapid tests if immediate action is required.

Alex: So, it sounds like mNGS and existing rapid tests will have to work in tandem. Could you highlight ‌any scenarios where mNGS shines, particularly in rare ⁢or undiagnosed ⁢cases?

Dr. Topka: Certainly! For infections like Borrelia burgdorferi, which⁤ cause Lyme disease, mNGS could be invaluable, especially ​since these pathogens are often difficult to culture ​in a lab. Similarly, in cases of environmental outbreaks or rare infections like​ amoebic​ encephalitis, this ⁤technology will allow clinicians to ‍identify pathogens that might otherwise go unnoticed.

Alex: It’s incredible how technology is evolving. How do you foresee the integration of ​mNGS into‍ standard clinical ‌practice?

Dr. Topka: The integration will depend on refining the technology, particularly to shorten⁤ turnaround times. As hospitals adopt mNGS and validate its⁢ efficacy in real-time clinical ​settings, ⁤we’ll see⁢ a shift towards routine use, especially in complicated or mysterious cases.

Alex: That transition must be exciting⁤ but challenging.​ With‍ the rise​ of mysterious cases in Germany, how do you believe this test will affect patient outcomes?

Dr.​ Topka: If we can make ​accurate‍ diagnoses more ‌quickly, we⁤ can initiate appropriate treatments sooner, significantly‍ improving outcomes for patients. However, it’s critical for healthcare providers to remain aware of the limitations of any diagnostic tool⁤ and use it in​ conjunction with clinical judgment​ and other methods.

Alex: Thank you, Dr. Topka, for shedding light ‍on this essential advancement in neurology. It’s reassuring to know ‍that our understanding of CNS infections is evolving, which can lead to better care for patients.

Dr. Topka: Thank you, ‌Alex! It’s a pleasure to discuss⁤ these ​developments, and I hope we can​ continue to innovate and improve⁢ patient care in the future.

Alex: ⁣Absolutely! We look forward to hearing more about the progress on ‌this front. Thank​ you‌ to our viewers for joining us—stay‌ tuned for more updates on advancements in medical science.

[The interview concludes as they smile and wave goodbye.]

You may also like

Leave a Comment